Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Teva B.V., Swensweg 5, 2031GA Haarlem, The Netherlands
Nevirapine Teva 200 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White, oval, biconvex tablets. One side is debossed with “N”, a scoreline and “200”. The opposite side is debossed with a scoreline. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each tablet contains 200 mg of nevirapine (as anhydrous).
Excipient with known effect: Each tablet contains 168 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
| Active Ingredient | Description | |
|---|---|---|
| Nevirapine |
Nevirapine is a NNRTI of HIV-1. Nevirapine is a non-competitive inhibitor of the HIV-1 reverse transcriptase, but it does not have a biologically significant inhibitory effect on the HIV-2 reverse transcriptase or on eukaryotic DNA polymerases α, β, γ, or δ. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Treatment initiation pack: White opaque PVC/PE/PVdC – Aluminium blisters or OPA/Alu/PVC – Aluminium blisters. Cartons containing 14 tablets (Calendar Pack).
Maintenance packs: White opaque PVC/PE/PVdC – Aluminium blisters or OPA/Alu/PVC – Aluminium blisters. Cartons containing 60 or 120 tablets.
Not all pack sizes may be marketed.
Teva B.V., Swensweg 5, 2031GA Haarlem, The Netherlands
EU/1/09/598/001-006
Date of first authorisation: 30 November 2009
Date of latest renewal: 26 August 2014
| Drug | Countries | |
|---|---|---|
| NEVIRAPINE | Nigeria |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
